Marinus Pharmaceuticals to be acquired by Immedica for 55c per share
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 30 2024
0mins
Should l Buy ?
Merger Agreement: Immedica Pharma has agreed to acquire Marinus Pharmaceuticals through a tender offer for $0.55 per share, representing a significant premium and an implied enterprise value of approximately $151 million. The transaction is expected to close in Q1 2025.
Strategic Approval: The board of directors of Marinus has unanimously approved the merger, with all directors and executive officers committed to tendering their shares, following Marinus' review of strategic alternatives announced in October.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
